Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (NASDAQ: BLUE) and Intersect ENT (NASDAQ: XENT)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bluebird Bio (NASDAQ: BLUE) and Intersect ENT (NASDAQ: XENT).

Bluebird Bio (NASDAQ: BLUE)

In a report issued on November 3, Cory Kasimov from J.P. Morgan reiterated a Buy rating on Bluebird Bio (NASDAQ: BLUE), with a price target of $120. The company’s shares closed last Friday at $42.55, close to its 52-week low of $35.37.

According to TipRanks.com, Kasimov is ranked 0 out of 5 stars with an average return of -15.8% and a 23.2% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Karyopharm Therapeutics, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Bluebird Bio is Strong Buy and the average price target is $103.50, representing a 143.2% upside.

In a report issued on October 25, Piper Jaffray also maintained a Buy rating on the stock with a $95 price target.
Intersect ENT (NASDAQ: XENT)

In a report issued on November 2, Sean Lavin from BTIG reiterated a Hold rating on Intersect ENT (NASDAQ: XENT). The company’s shares closed last Friday at $10.45.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 11.1% and a 60.9% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Boston Scientific Corp.

Currently, the analyst consensus on Intersect ENT is Moderate Buy and the average price target is $17, representing a 62.7% upside.

In a report issued on October 18, Deutsche Bank also reiterated a Hold rating on the stock with a $17 price target.